

8 August 2023



Universal Biosensors signs five more Petrackr distribution deals

Universal Biosensors, Inc. (ASX: UBI) advises since our last market update UBI has signed an additional 5 distribution deals with partners in 3 countries for Petrackr, UBI's blood glucose monitoring product for dogs and cats with diabetes.

We now have 8 distribution deals in total and received purchase orders of \$480,000 in the first two months since launch. First year sales value from these 8 deals is expected to exceed \$4 million with sales growth expected in the following years.

Mr John Sharman, CEO of UBI said; "We are very pleased with the initial response to our global launch. We are confident that "Petrackr" provides customers with a better alternative in terms of price, accuracy, latest technology, user mobile application and overall performance compared to the current products available in the market."

For further information please refer to the PETRACKR website (<https://www.universalbiosensors.com/products/petrackr/>).

End

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

For further information contact:

John Sharman
Chief Executive Officer
+61 (0) 414 440 680

About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.